The possibility of combining CAR-T therapy and bispecific antibodies in the treatment of NHL

Update on Follicular Lymphoma | LRF WebinarsПодробнее

Combining CAR-Ts & bispecific antibodiesПодробнее

The promise of bispecific antibodies in the treatment of NHLПодробнее

What are the differences between CAR T-cell therapy and bispecific antibodies?Подробнее

How will bispecifics impact the treatment of NHL?Подробнее

Optimal sequencing of CAR-T and bispecifics in NHLПодробнее

Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodiesПодробнее

Clinical guidance for the use of bispecific antibodies in NHLПодробнее

Moving CAR T-cell therapy and bispecific antibodies in the consolidation settingПодробнее

The CAR T-cell strategy vs bispecific antibodiesПодробнее

The development of CD79b-targeting CAR T-cells for the treatment of NHLПодробнее

Advancements and challenges in bispecific antibodies for the treatment of B-NHLПодробнее

The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALLПодробнее

Bispecifics & CAR-T therapy in DLBCL: sequencing and selecting between these agentsПодробнее

Mosunetuzumab in B-NHL R/R to CAR-TПодробнее

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHLПодробнее

Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodiesПодробнее

Bispecific antibodies in NHL: current insights and ongoing studiesПодробнее

Sequencing bispecific antibodies and CAR-T therapy & the evolving role of bispecifics in myelomaПодробнее

Replacing ASCT: CAR-T or bispecific antibodies?Подробнее